Literature DB >> 33624009

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.

Martin Wermke1,2, Sabrina Kraus3, Armin Ehninger4, Ralf C Bargou5, Maria-Elisabeth Goebeler5, Jan Moritz Middeke1,2, Carla Kreissig6, Malte von Bonin1,2, Jan Koedam4, Michael Pehl4, Martin Bornhäuser1,2, Hermann Einsele3, Gerhard Ehninger4, Marc Cartellieri4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33624009      PMCID： PMC8176767          DOI： 10.1182/blood.2020009759

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  18 in total

1.  Bayesian optimal interval design for dose finding in drug-combination trials.

Authors:  Ruitao Lin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2015-07-15       Impact factor: 3.021

2.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 4.  Toxicities of chimeric antigen receptor T cells: recognition and management.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

5.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

6.  Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

Authors:  A Ehninger; M Kramer; C Röllig; C Thiede; M Bornhäuser; M von Bonin; M Wermke; A Feldmann; M Bachmann; G Ehninger; U Oelschlägel
Journal:  Blood Cancer J       Date:  2014-06-13       Impact factor: 11.037

7.  Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Authors:  Katherine D Cummins; Saar Gill
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

8.  41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.

Authors:  Matteo Libero Baroni; Diego Sanchez Martinez; Francisco Gutierrez Aguera; Heleia Roca Ho; Maria Castella; Samanta Romina Zanetti; Talia Velasco Hernandez; Rafael Diaz de la Guardia; Julio Castaño; Eduardo Anguita; Susana Vives; Josep Nomdedeu; Helene Lapillone; Anne E Bras; Vincent H J van der Velden; Jordi Junca; Pedro Marin; Alex Bataller; Jordi Esteve; Binje Vick; Irmela Jeremias; Angel Lopez; Marc Sorigue; Clara Bueno; Pablo Menendez
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

9.  Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.

Authors:  M Cartellieri; A Feldmann; S Koristka; C Arndt; S Loff; A Ehninger; M von Bonin; E P Bejestani; G Ehninger; M P Bachmann
Journal:  Blood Cancer J       Date:  2016-08-12       Impact factor: 11.037

10.  Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.

Authors:  Simon Loff; Josephine Dietrich; Jan-Erik Meyer; Julia Riewaldt; Johannes Spehr; Malte von Bonin; Cordula Gründer; Mridula Swayampakula; Kristin Franke; Anja Feldmann; Michael Bachmann; Gerhard Ehninger; Armin Ehninger; Marc Cartellieri
Journal:  Mol Ther Oncolytics       Date:  2020-04-29       Impact factor: 7.200
View more
  22 in total

Review 1.  Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.

Authors:  Alexander Michels; Naphang Ho; Christian J Buchholz
Journal:  Mol Ther       Date:  2022-05-20       Impact factor: 12.910

Review 2.  Application and Design of Switches Used in CAR.

Authors:  Paweł Głowacki; Piotr Rieske
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

Review 3.  Synthetic receptors for logic gated T cell recognition and function.

Authors:  Sylvain Simon; Grace Bugos; Alex I Salter; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2021-09-24       Impact factor: 7.486

4.  Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.

Authors:  Claudia Arndt; Ralf Bergmann; Franziska Striese; Keresztély Merkel; Domokos Máthé; Liliana R Loureiro; Nicola Mitwasi; Alexandra Kegler; Frederick Fasslrinner; Karla Elizabeth González Soto; Christin Neuber; Nicole Berndt; Noemi Kovács; David Szöllősi; Nikolett Hegedűs; Gyula Tóth; Jan-Philipp Emmermann; Kuzhuvelil B Harikumar; Tibor Kovacs; Michael Bachmann; Anja Feldmann
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 5.  Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia.

Authors:  Matthias Böhme; Sabine Kayser
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

Review 6.  Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.

Authors:  Yishan Ye; Luxin Yang; Xiaolin Yuan; He Huang; Yi Luo
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

7.  Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.

Authors:  Jan-Erik Meyer; Simon Loff; Josephine Dietrich; Johannes Spehr; Gabriel Jurado Jiménez; Malte von Bonin; Gerhard Ehninger; Marc Cartellieri; Armin Ehninger
Journal:  Oncoimmunology       Date:  2021-07-08       Impact factor: 8.110

Review 8.  iNKT: A new avenue for CAR-based cancer immunotherapy.

Authors:  Yilin Liu; Gang Wang; Dafei Chai; Yuanyuan Dang; Junnian Zheng; Huizhong Li
Journal:  Transl Oncol       Date:  2022-01-18       Impact factor: 4.243

Review 9.  Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.

Authors:  Marius Maucher; Micha Srour; Sophia Danhof; Hermann Einsele; Michael Hudecek; Ibrahim Yakoub-Agha
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

Review 10.  Advances in Universal CAR-T Cell Therapy.

Authors:  Haolong Lin; Jiali Cheng; Wei Mu; Jianfeng Zhou; Li Zhu
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.